VIGOR trial

VIGOR trial
Name	VIGOR
Disease	Rheumatoid arthritis
Status	Completed
Sponsor	Merck & Co.
Investigators	Claire Bombardier
Phase	Phase III
Published	2000
Outcome	Gastrointestinal safety
Interventions	Rofecoxib vs. Naproxen
Design	Randomized, double-blind
Size	8,076

VIGOR trial. The VIGOR trial was a pivotal Phase III randomized controlled trial that compared the cyclooxygenase-2 inhibitor rofecoxib (marketed as Vioxx) to the traditional nonsteroidal anti-inflammatory drug naproxen in patients with rheumatoid arthritis. Sponsored by Merck & Co., its primary aim was to demonstrate superior gastrointestinal safety for the new agent. The trial's unexpected findings regarding cardiovascular risk precipitated a major controversy in pharmacovigilance and led to significant changes in drug safety regulations.

Background and Rationale

By the late 1990s, nonsteroidal anti-inflammatory drugs like ibuprofen and naproxen were widely used but carried a significant risk of serious gastrointestinal complications, including peptic ulcer disease and gastrointestinal bleeding. Merck & Co. developed rofecoxib, a selective cyclooxygenase-2 inhibitor, theorized to provide anti-inflammatory and analgesic effects while sparing the cyclooxygenase-1 enzyme protective to the gastric mucosa. The hypothesis, supported by earlier endoscopy studies, was that this mechanism would yield a better safety profile. The trial was designed to provide definitive evidence for this gastrointestinal advantage in a high-risk population with rheumatoid arthritis, a condition often requiring chronic NSAID therapy.

Trial Design and Methodology

The VIGOR trial was a multinational, randomized, double-blind, parallel-group study conducted at numerous sites internationally. It enrolled 8,076 patients with rheumatoid arthritis who were not taking aspirin for cardiovascular protection. Participants were randomly assigned to receive either 50 mg of rofecoxib once daily or 500 mg of naproxen twice daily. The pre-specified primary endpoint was the incidence of clinically significant gastrointestinal events, such as perforation, obstruction, or severe upper gastrointestinal bleeding. Secondary assessments included efficacy in managing arthritis symptoms. The trial's Data and Safety Monitoring Board oversaw patient safety during the conduct of the study.

Results and Primary Outcomes

The results, published in *The New England Journal of Medicine* in 2000, confirmed the primary hypothesis. The trial demonstrated a statistically significant reduction in the risk of confirmed gastrointestinal events for patients taking rofecoxib compared to those on naproxen. The incidence was approximately half in the rofecoxib group, a finding that strongly supported the drug's proposed safety advantage. In terms of efficacy for rheumatoid arthritis, both treatments showed similar results in relieving pain and improving function. These positive gastrointestinal outcomes were initially hailed as a major advance in the treatment of chronic inflammatory conditions.

Safety Findings and Cardiovascular Events

A pre-specified secondary analysis revealed a surprising and concerning safety signal. Patients in the rofecoxib arm experienced a significantly higher rate of serious thrombotic events, including myocardial infarction and ischemic stroke, compared to the naproxen group. The investigators and Merck & Co. posited that this difference might be due to a protective antiplatelet effect of naproxen, rather than a harmful effect of rofecoxib. This interpretation was debated within the medical community, with critics arguing the data suggested a pro-thrombotic risk inherent to cyclooxygenase-2 inhibitors. The discrepancy in cardiovascular outcomes became the central focus of intense scientific and regulatory scrutiny.

Aftermath and Regulatory Impact

The cardiovascular findings triggered a prolonged scientific and public debate. Regulatory agencies, including the U.S. Food and Drug Administration and the European Medicines Agency, reviewed the data and updated rofecoxib's labeling to include warnings. Subsequent studies, such as the APPROVe trial, provided confirmatory evidence of an increased risk of myocardial infarction and stroke. In September 2004, Merck & Co. voluntarily withdrew rofecoxib from the global market. The controversy led to congressional hearings in the United States Senate and a re-evaluation of post-marketing surveillance systems. It also resulted in numerous product liability lawsuits against the manufacturer.

Scientific and Medical Legacy

The VIGOR trial left an indelible mark on clinical research and regulatory science. It underscored the critical importance of adequately assessing cardiovascular safety for all new anti-inflammatory drugs, leading to more rigorous FDA guidance for drug development. The case became a seminal teaching example in medical ethics, pharmacoepidemiology, and the responsibilities of pharmaceutical industry sponsors in reporting trial data. It accelerated the adoption of large, outcomes trials to evaluate drug safety and permanently altered the risk-benefit calculus for the entire class of cyclooxygenase-2 inhibitors, influencing prescribing practices worldwide.

Category:Clinical trials Category:Drug safety Category:Medical controversies